Filing summary
Entity and period mismatch: The supplied filing is AntriaBio, Inc.’s Form 10-K for the fiscal year ended June 30, 2016, filed September 28, 2016. It is not identified in the filing as a Rezolute, Inc. filing, and it does not report a “2015 Q4” period. Verify the issuer and reporting period before relying on this summary.
Business context and reporting period
AntriaBio was a preclinical biopharmaceutical company developing sustained-release injectable therapies. Its lead candidate, AB101, is a proposed once-weekly basal insulin for Type 1 and Type 2 diabetes. AB301, a proposed weekly GLP-1 agonist and AB101 combination, remained in preclinical development. The company had no commercial products or revenue.
Financial results and liquidity
| Metric | FY ended June 30, 2016 | FY ended June 30, 2015 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $9.45 million | $4.70 million |
| General and administrative expense | $5.50 million | $6.00 million |
| Operating loss | $14.95 million | $10.70 million |
| Net loss | $14.94 million | $11.36 million |
| Net loss attributable to common stock | $20.91 million | $11.36 million |
| Basic and diluted loss per share | $0.84 | $0.54 |
| Cash used in operating activities | $10.49 million | $7.08 million |
| Cash used in investing activities | $1.45 million | $3.61 million |
| Cash provided by financing activities | $10.73 million | $10.04 million |
R&D spending approximately doubled, driven by staffing and increased manufacturing and development work. G&A expense declined, primarily because the company stopped using certain consultants. The additional $5.97 million loss attributable to common stock reflected cumulative preferred-stock dividends; the preferred shares were converted and exchanged for common shares and warrants in June 2016, with an approximately $5.81 million deemed dividend recorded.
At June 30, 2016, cash was $4.06 million and working capital was approximately $2.8 million. Total assets were $10.90 million, total liabilities $2.13 million, and stockholders’ equity $8.77 million. The company reported $60,000 of matured convertible notes, accruing interest at 8%, as well as lease liabilities and $1.48 million of remaining operating lease commitments. No off-balance-sheet arrangements were reported.
Material changes and unusual items
- Net loss increased from $11.36 million to $14.94 million, while operating cash use rose from $7.08 million to $10.49 million.
- The company completed construction of its manufacturing suite and recorded $5.98 million in net fixed assets. It reported $2.09 million of fixed-asset purchases during FY2016.
- Series A preferred stock financing and other equity transactions provided substantial financing, but the preferred stock was converted and exchanged for common stock and warrants in June 2016. The transaction included a deemed dividend and a gain recorded in additional paid-in capital.
- Common shares outstanding rose to 35.11 million at fiscal year-end from 24.34 million a year earlier. The filing also reports 33.46 million common-stock equivalents outstanding at June 30, 2016, excluded from diluted loss per share as anti-dilutive.
Outlook, risks, and contingencies
- Funding and going concern: The auditor’s report and the financial statements disclose substantial doubt about the company’s ability to continue as a going concern. Management said it needed at least $15 million in additional capital to fund operations and development through December 2017; no assurance was given that financing would be available. The filing says cash resources and expected operating cash flows would not sustain operations for more than one year.
- AB101 timing: The company reported clinical-scale sample batches in calendar 2016 but still needed to qualify sterility and its manufacturing process. It planned to complete facility qualification by the end of Q1 2017, then file an IND and begin a clinical study in the first half of 2017, subject to financing and manufacturing readiness. These were plans, not achieved milestones.
- AB301: Preclinical work was ongoing; the company was monitoring FDA review of potential competing combination therapies before undertaking IND-enabling studies.
- Key execution risks: Clinical and regulatory failure or delay, manufacturing validation and cGMP compliance, dependence on suppliers and outside trial providers, competition from established pharmaceutical companies, need for further financing and likely dilution, and uncertain intellectual-property and commercial prospects.
- Controls: Management concluded disclosure controls and internal control over financial reporting were not effective, citing a material weakness involving inadequate segregation of duties and insufficient review of the chief accounting officer’s work. Remediation was underway but not assured.
- Other matters: A conditional regional AB101 license for pH Pharma, whose CEO and majority owner was also an AntriaBio director, would take effect only after pH Pharma purchased at least $8 million of company securities; it had invested $2 million by year-end. The filing reported no material pending litigation.
Important facts for investors to verify
- Confirm that AntriaBio’s FY2016 10-K—not a Rezolute filing or a 2015 Q4 report—is the intended document.
- Check subsequent filings for actual fundraising, cash runway, share and warrant dilution, and the status of the conditional pH Pharma investment and license.
- Verify whether the manufacturing facility achieved sterile-process qualification, whether an IND was filed, and whether the planned AB101 clinical study began.
- Review subsequent disclosures on going-concern status and remediation of the reported material weakness in financial controls.